A diagnostic lab brand in a box is a proposed model for offering branded testing services using existing ordering, collection, laboratory and results infrastructure. The storefront is only one part: a viable service must define who can order each test, which laboratory performs it, how results reach the right people and who handles clinical follow-up.

What are the components of a branded diagnostics service?

A customer sees a test description, a price and a way to begin. Behind those steps, the business must connect eligibility, ordering authority, collection instructions, specimen handling, laboratory testing, result delivery and any promised clinical interpretation. If one part is missing, a polished storefront cannot complete the service.

ComponentQuestion to resolve
Test offerWhich panel, intended use and customer population are supported?
OrderingWho may authorize the test in the customer’s jurisdiction?
CollectionAt-home kit, collection site or another documented method?
TestingWhich laboratory performs the work and under what credentials?
Results and follow-upWho receives, explains and escalates findings?

A platform discussion should address each layer. The TEHR platform connects lab workflows with broader health-brand operations, but the exact diagnostic services and partner arrangement must be scoped rather than inferred from a category label.

Is owning a diagnostics brand the same as operating a laboratory?

No. A company can market a branded experience while an independent laboratory performs the testing. That distinction should be clear in contracts and customer-facing materials. A logo on the kit or portal does not establish that the brand owns or operates the laboratory.

CMS guidance on direct-access testing and CLIA explains that facilities performing patient testing need the appropriate CLIA certificate. Ordering authority remains a separate state-law question. These requirements should be checked for the actual testing and service model.

Ask for the laboratory’s identity and relevant documentation, then verify that the proposed tests and collection methods match the agreement. Avoid vague statements that a brand is “CLIA approved” simply because it works with a laboratory. The responsible parties should describe their own roles accurately. Our clinical infrastructure guide explains the parallel distinction between a branded service and medical practice.

How should you select the initial test offering?

Start with the customer problem and the service you intend to provide. A broad panel may look attractive in marketing, but it also creates more information that must be explained, delivered and handled appropriately. The number of biomarkers is not a substitute for a defined purpose.

Ask clinical and laboratory partners to review the proposed panel, eligibility and collection method. Decide whether the service is standalone testing, part of an ongoing clinical program or an educational offering with a separate care pathway. The customer should understand which model applies before purchase.

Keep the first catalog manageable. Each additional test can introduce different instructions, specimen requirements, turnaround expectations and follow-up arrangements. The business needs to maintain those details accurately. If your brand already serves a defined audience, use that knowledge to form questions for the clinical team rather than select tests solely because they fit a marketing trend.

What does the collection experience need to cover?

Collection is where a digital promise becomes a physical process. The customer needs clear instructions, the right materials and a way to get help. An at-home kit, an in-person draw and mobile collection create different operational dependencies. Do not describe them as interchangeable fulfillment options.

For a kit-based service, map dispatch, delivery, registration, collection, return shipping and specimen receipt. Define what happens when a kit arrives late, a customer cannot complete collection, the sample is insufficient or a return package is delayed. These events affect both support workload and customer expectations.

For location-based collection, explain how the customer finds an eligible location, what documentation is needed and how the order is recognized. Test the instructions with someone unfamiliar with the process. A diagnostics brand should know the full path from purchase to accepted specimen, not only whether a package was shipped or an order was placed.

How should results and clinical follow-up be designed?

Define the recipients and timing for results before accepting orders. The customer may need secure portal access, while an ordering clinician may have separate review responsibilities. If interpretation is included, explain who provides it, what format it takes and how the customer requests additional help.

Build a distinct pathway for findings that require urgent attention. The laboratory and clinical partners should define their responsibilities and communication procedures. A routine marketing email or an unattended support inbox is not an adequate design for every type of result. Your operating team needs to understand its role without trying to interpret results outside its competence.

Also decide how corrected or amended reports are handled. A result can be updated after the first version is released, and the system should preserve a clear record of what changed and who was notified. The patient experience is complete only when the intended result and follow-up workflow have occurred, not merely when a PDF becomes available.

What public diagnostic offerings are related to TEHR’s ecosystem?

As of October 22, 2026, TEERx’s public site lists TellyLabs as a diagnostics holding. TellyLabs presents a consumer testing storefront, and its partnership page invites collaboration with telemedicine clinics and healthcare providers.

Those public offerings are relevant context, but they do not establish the scope of a standalone TEHR diagnostic-brand product. A prospective operator should ask about the actual services available for its business, the contracting parties and how ordering, testing and results would connect to the proposed platform.

The DudeMeds lab page distinguishes lab work associated with a care program from standalone testing through TellyLabs. That is a useful distinction for buyers: included program labs and a separate diagnostic purchase can have different prices, instructions and service responsibilities. Do not combine them into one assumed offer.

How do privacy and records affect the service?

A test purchase can generate customer, payment, ordering and laboratory information across several organizations. Identify what each party receives and why. A customer-service employee may need a kit status without needing access to the full report. Marketing tools should not automatically receive the same information as clinical systems.

Review the appropriate agreements for the actual relationships. HHS business-associate guidance provides context for permitted handling and safeguards where those arrangements apply. The brand should also assess its consumer-data practices rather than assume every activity is governed identically.

Plan for patient access, account recovery and retention. If a customer loses access to the branded portal or the business changes platforms, the records process still needs to work. The migration checklist is useful for thinking through identifiers, historical reports, attachments and continuing access even before the first customer enrolls.

How should you model costs and customer expectations?

Separate the test price from the complete service cost. Relevant components may include ordering, collection materials, shipping, laboratory processing, result delivery, interpretation, support and replacements. The actual quote should identify what is included and when additional charges can arise.

Model exception costs as well as the routine journey. An unsuccessful collection, replacement kit or unreturned specimen can consume support and fulfillment resources. Decide how the customer is informed and what the commercial policy is. A clear offer should not leave customers guessing whether paying for a test guarantees a usable specimen or a particular clinical conclusion.

Use the operating cost guide to structure the budget, and discuss platform terms through TEHR pricing. Contact TEHR for a scoped quote. A diagnostic proposal needs its own service assumptions; ordinary prescription-program economics should not be copied without accounting for the different workflow.

What should a diagnostic-brand launch checklist include?

Begin with a specific test catalog, intended jurisdictions, ordering model and named testing partners. Confirm collection instructions, eligibility messages, required disclosures and the full result-delivery process. Assign owners for customer support, specimen exceptions, amended reports and urgent communications.

Run a complete test of the operational journey using an agreed nonpatient or demonstration process. Verify that identifiers connect the correct order, kit and report. Check the customer’s instructions and the staff view of each status. Document how a failed step is discovered and resolved.

The health-brand package guide helps separate commercial and service responsibilities, while the launch planning guide explains milestone gates. Use those frameworks to prepare a scoped discussion. A launch should follow a validated service model rather than treating a diagnostic storefront as proof that ordering, laboratory and follow-up requirements have already been solved.

What else should you know?

Does this guide mean TEHR offers a live lab-brand package?

No. This guide explains the operating model and the questions a buyer should resolve. Discuss current TEHR lab workflows, partner arrangements and available services directly. A public diagnostics-related relationship does not establish a specific purchasable package, price or nationwide test catalog.

Can customers order any test directly?

Do not assume universal direct access. Ordering requirements depend on the jurisdiction, test and service model. Identify the authorized ordering pathway with the responsible clinical and laboratory partners before advertising availability or configuring a self-service checkout for a particular panel.

Is the brand the same entity as the laboratory?

Not necessarily. A brand may provide the storefront and customer experience while another organization performs testing. The agreement and disclosures should identify the actual laboratory and responsibilities. A branded kit or portal does not transfer the laboratory’s credentials to the brand.

Are at-home tests and in-person collection interchangeable?

No. They can differ in specimen requirements, instructions, logistics and available testing. Confirm the method supported for each offering and explain it accurately. A change in collection approach should be reviewed with the relevant partners rather than made as an ordinary shipping substitution.

Should a larger biomarker panel be the main selling point?

Panel size alone does not explain suitability or value. Start with the intended purpose, supported service and follow-up model. The customer should understand what information is provided, who reviews it and what happens next, without promises of diagnosis or outcomes that the service cannot support.

What should an existing brand bring to a diagnostics discussion?

Bring its audience, intended use cases, planned states, current clinical relationships and proposed customer journey. Also identify whether testing is standalone or attached to ongoing care. Those details help establish the right ordering, collection, results and commercial model.

Which sources support this guide?

Public sources reviewed as of 2026-10-22. Vendor statements describe the vendor’s published offering; your contract determines actual scope.

Build around your operation.

Discuss your categories, patient experience and costs with TEHR.